Venezuelan equine encephalitis replicon particles can induce rapid protection against foot-and-mouth disease virus. 2013

Fayna Diaz-San Segundo, and Camila C A Dias, and Mauro P Moraes, and Marcelo Weiss, and Eva Perez-Martin, and Gary Owens, and Max Custer, and Kurt Kamrud, and Teresa de los Santos, and Marvin J Grubman
Plum Island Animal Disease Center, North Atlantic Area, Agricultural Research Service, US Department of Agriculture, Greenport, New York, USA.

We have previously shown that delivery of the porcine type I interferon gene (poIFN-α/β) with a replication-defective human adenovirus vector (adenovirus 5 [Ad5]) can sterilely protect swine challenged with foot-and-mouth disease virus (FMDV) 1 day later. However, the need of relatively high doses of Ad5 limits the applicability of such a control strategy in the livestock industry. Venezuelan equine encephalitis virus (VEE) empty replicon particles (VRPs) can induce rapid protection of mice against either homologous or, in some cases, heterologous virus challenge. As an alternative approach to induce rapid protection against FMDV, we have examined the ability of VRPs containing either the gene for green fluorescent protein (VRP-GFP) or poIFN-α (VRP-poIFN-α) to block FMDV replication in vitro and in vivo. Pretreatment of swine or bovine cell lines with either VRP significantly inhibited subsequent infection with FMDV as early as 6 h after treatment and for at least 120 h posttreatment. Furthermore, mice pretreated with either 10(7) or 10(8) infectious units of VRP-GFP and challenged with a lethal dose of FMDV 24 h later were protected from death. Protection was induced as early as 6 h after treatment and lasted for at least 48 h and correlated with induction of an antiviral response and production of IFN-α. By 6 h after treatment several genes were upregulated, and the number of genes and the level of induction increased at 24 h. Finally, we demonstrated that the chemokine IP-10, which is induced by IFN-α and VRP-GFP, is directly involved in protection against FMDV.

UI MeSH Term Description Entries
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004666 Encephalitis Virus, Venezuelan Equine A species of ALPHAVIRUS that is the etiologic agent of encephalomyelitis in humans and equines. It is seen most commonly in parts of Central and South America. Encephalomyelitis Virus, Venezuelan Equine,Encephalitis Viruses, Venezuelan Equine,Venezuelan Equine Encephalitis Viruses,Venezuelan equine encephalitis virus,Virus, Venezuelan Equine Encephalitis,Viruses, Venezuelan Equine Encephalitis
D005536 Foot-and-Mouth Disease A highly infectious disease caused by FOOT AND MOUTH DISEASE VIRUS that affects mammals of the ARTIODACTYLA order (CATTLE; SHEEP; GOATS; and PIGS) and is characterized by high fever followed by the appearance of blisters inside the mouth and on the feet. Foot and Mouth Disease,Disease, Foot-and-Mouth,Diseases, Foot-and-Mouth,Foot-and-Mouth Diseases
D005822 Genetic Vectors DNA molecules capable of autonomous replication within a host cell and into which other DNA sequences can be inserted and thus amplified. Many are derived from PLASMIDS; BACTERIOPHAGES; or VIRUSES. They are used for transporting foreign genes into recipient cells. Genetic vectors possess a functional replicator site and contain GENETIC MARKERS to facilitate their selective recognition. Cloning Vectors,Shuttle Vectors,Vectors, Genetic,Cloning Vector,Genetic Vector,Shuttle Vector,Vector, Cloning,Vector, Genetic,Vector, Shuttle,Vectors, Cloning,Vectors, Shuttle
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D015316 Genetic Therapy Techniques and strategies which include the use of coding sequences and other conventional or radical means to transform or modify cells for the purpose of treating or reversing disease conditions. Gene Therapy,Somatic Gene Therapy,DNA Therapy,Gene Therapy, Somatic,Genetic Therapy, Gametic,Genetic Therapy, Somatic,Therapy, DNA,Therapy, Gene,Therapy, Somatic Gene,Gametic Genetic Therapies,Gametic Genetic Therapy,Genetic Therapies,Genetic Therapies, Gametic,Genetic Therapies, Somatic,Somatic Genetic Therapies,Somatic Genetic Therapy,Therapies, Gametic Genetic,Therapies, Genetic,Therapies, Somatic Genetic,Therapy, Gametic Genetic,Therapy, Genetic,Therapy, Somatic Genetic
D016019 Survival Analysis A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function. Analysis, Survival,Analyses, Survival,Survival Analyses
D016898 Interferon-alpha One of the type I interferons produced by peripheral blood leukocytes or lymphoblastoid cells. In addition to antiviral activity, it activates NATURAL KILLER CELLS and B-LYMPHOCYTES, and down-regulates VASCULAR ENDOTHELIAL GROWTH FACTOR expression through PI-3 KINASE and MAPK KINASES signaling pathways. Interferon Alfa,Interferon, Leukocyte,Interferon, Lymphoblast,alpha-Interferon,IFN-alpha D,IFN-alpha5,Interferon alpha-1,Interferon alpha-17,Interferon alpha-4,Interferon alpha-5,Interferon alpha-7,Interferon alpha-88,Interferon alpha-J,Interferon alpha-T,Interferon alpha4,Interferon alpha5,Interferon, Lymphoblastoid,Interferon, alpha,LeIF I,LeIF J,Leif D,IFN alpha D,IFN alpha5,Interferon alpha,Interferon alpha 1,Interferon alpha 17,Interferon alpha 4,Interferon alpha 5,Interferon alpha 7,Interferon alpha 88,Interferon alpha J,Interferon alpha T,Leukocyte Interferon,Lymphoblast Interferon,Lymphoblastoid Interferon,alpha Interferon
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

Fayna Diaz-San Segundo, and Camila C A Dias, and Mauro P Moraes, and Marcelo Weiss, and Eva Perez-Martin, and Gary Owens, and Max Custer, and Kurt Kamrud, and Teresa de los Santos, and Marvin J Grubman
January 2000, Journal of virology,
Fayna Diaz-San Segundo, and Camila C A Dias, and Mauro P Moraes, and Marcelo Weiss, and Eva Perez-Martin, and Gary Owens, and Max Custer, and Kurt Kamrud, and Teresa de los Santos, and Marvin J Grubman
May 2009, Journal of virology,
Fayna Diaz-San Segundo, and Camila C A Dias, and Mauro P Moraes, and Marcelo Weiss, and Eva Perez-Martin, and Gary Owens, and Max Custer, and Kurt Kamrud, and Teresa de los Santos, and Marvin J Grubman
April 2002, The Journal of infectious diseases,
Fayna Diaz-San Segundo, and Camila C A Dias, and Mauro P Moraes, and Marcelo Weiss, and Eva Perez-Martin, and Gary Owens, and Max Custer, and Kurt Kamrud, and Teresa de los Santos, and Marvin J Grubman
December 2007, Journal of virology,
Fayna Diaz-San Segundo, and Camila C A Dias, and Mauro P Moraes, and Marcelo Weiss, and Eva Perez-Martin, and Gary Owens, and Max Custer, and Kurt Kamrud, and Teresa de los Santos, and Marvin J Grubman
July 2008, PloS one,
Fayna Diaz-San Segundo, and Camila C A Dias, and Mauro P Moraes, and Marcelo Weiss, and Eva Perez-Martin, and Gary Owens, and Max Custer, and Kurt Kamrud, and Teresa de los Santos, and Marvin J Grubman
January 2004, Vaccine,
Fayna Diaz-San Segundo, and Camila C A Dias, and Mauro P Moraes, and Marcelo Weiss, and Eva Perez-Martin, and Gary Owens, and Max Custer, and Kurt Kamrud, and Teresa de los Santos, and Marvin J Grubman
June 2009, Vaccine,
Fayna Diaz-San Segundo, and Camila C A Dias, and Mauro P Moraes, and Marcelo Weiss, and Eva Perez-Martin, and Gary Owens, and Max Custer, and Kurt Kamrud, and Teresa de los Santos, and Marvin J Grubman
November 2006, Vaccine,
Fayna Diaz-San Segundo, and Camila C A Dias, and Mauro P Moraes, and Marcelo Weiss, and Eva Perez-Martin, and Gary Owens, and Max Custer, and Kurt Kamrud, and Teresa de los Santos, and Marvin J Grubman
December 2009, Journal of virology,
Fayna Diaz-San Segundo, and Camila C A Dias, and Mauro P Moraes, and Marcelo Weiss, and Eva Perez-Martin, and Gary Owens, and Max Custer, and Kurt Kamrud, and Teresa de los Santos, and Marvin J Grubman
March 2008, Vaccine,
Copied contents to your clipboard!